IL282069A - Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators - Google Patents

Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators

Info

Publication number
IL282069A
IL282069A IL282069A IL28206921A IL282069A IL 282069 A IL282069 A IL 282069A IL 282069 A IL282069 A IL 282069A IL 28206921 A IL28206921 A IL 28206921A IL 282069 A IL282069 A IL 282069A
Authority
IL
Israel
Prior art keywords
chaperone
benzoxazole
useful
related compounds
mediated autophagy
Prior art date
Application number
IL282069A
Other languages
English (en)
Hebrew (he)
Original Assignee
Albert Einstein College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Medicine filed Critical Albert Einstein College Medicine
Publication of IL282069A publication Critical patent/IL282069A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL282069A 2018-10-10 2021-04-05 Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators IL282069A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862743920P 2018-10-10 2018-10-10
PCT/US2019/055493 WO2020077024A1 (en) 2018-10-10 2019-10-10 Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators

Publications (1)

Publication Number Publication Date
IL282069A true IL282069A (en) 2021-05-31

Family

ID=70163886

Family Applications (1)

Application Number Title Priority Date Filing Date
IL282069A IL282069A (en) 2018-10-10 2021-04-05 Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators

Country Status (11)

Country Link
US (1) US12473266B2 (cg-RX-API-DMAC7.html)
EP (1) EP3863755A4 (cg-RX-API-DMAC7.html)
JP (1) JP7503850B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210082466A (cg-RX-API-DMAC7.html)
CN (1) CN113195084B (cg-RX-API-DMAC7.html)
AU (1) AU2019358074A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021006843A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115297A1 (cg-RX-API-DMAC7.html)
IL (1) IL282069A (cg-RX-API-DMAC7.html)
MX (1) MX2021004134A (cg-RX-API-DMAC7.html)
WO (1) WO2020077024A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022015624A1 (en) * 2020-07-16 2022-01-20 Schrödinger, Inc. Substituted dihydropyrazinediones as modulators of the nmda receptor
JP2023551435A (ja) * 2020-11-20 2023-12-08 エフ. ホフマン-ラ ロシュ アーゲー B型肝炎ウイルス感染症の処置及び予防のためのn置換4-(1,3-アリールオキサゾロ-2-イル)フェニル化合物
WO2022155333A1 (en) * 2021-01-13 2022-07-21 Albert Einstein College Of Medicine Use of chaperone-mediated autophagy activators for treating or preventing blood cancers and myelodysplastic syndromes
EP4326267A4 (en) * 2021-04-21 2025-07-09 Albert Einstein College Medicine METHOD FOR INCREASING CHAPERONE-MEDIATED AUTOPHAGY BY STABILIZING THE INTERACTION BETWEEN THE RETINOIC ACID RECEPTOR ALPHA AND AN INHIBITOR
KR102778740B1 (ko) 2021-06-24 2025-03-07 주식회사 엘지화학 합성가스의 제조방법
CN114404421B (zh) * 2022-02-28 2023-04-28 同济大学 选择性自噬激活剂qx77在制备干预或治疗糖尿病视网膜病变的药物中的应用
WO2024225738A1 (ko) * 2023-04-25 2024-10-31 부산대학교 산학협력단 지방간질환 치료 또는 예방 목적의 fxr/ppar alpha 이중 작용 활성을 가지는 벤즈옥사졸 유도체 화합물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH469802A (de) * 1966-01-07 1969-03-15 Ciba Geigy Verwendung von Benzoxazol-Derivaten als Scintillator-Substanzen
US5428052A (en) * 1984-09-19 1995-06-27 Centre Internationale De Recherches Dermatologiques (C.I.R.D.) Aromatic heterocyclic derivatives and their therapeutic and cosmetic use
ATE240942T1 (de) * 1995-11-17 2003-06-15 Merck & Co Inc Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren
AU2002365892A1 (en) * 2001-11-30 2003-06-17 Merck & Co., Inc. Metabotropic glutamate receptor-5 modulators
KR20040096601A (ko) 2002-02-21 2004-11-16 시바 스페셜티 케미칼스 홀딩 인크. 락탐계 안료 및 착색된 플라스틱 또는 중합체성 착색입자의 제조시 이의 용도
JP4903133B2 (ja) 2004-04-30 2012-03-28 ジェネンテック,インコーポレイティド ヘッジホッグシグナル伝達のキノキサリン阻害剤
UA91341C2 (ru) * 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
EP1954287B2 (en) 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Cetp inhibitors
BRPI0707719A2 (pt) * 2006-02-10 2011-05-10 Summit Corp Plc uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo
GB0602768D0 (en) * 2006-02-10 2006-03-22 Vastox Plc Treatment of muscular dystrophy
RU2462458C2 (ru) * 2006-02-10 2012-09-27 Байомарин Ига Лимитед Лечение миодистрофии дюшена
AR066879A1 (es) 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
AU2008285289A1 (en) 2007-08-03 2009-02-12 Biomarin Iga Limited Drug combinations for the treatment of Duchenne muscular dystrophy
MX2011002647A (es) 2008-09-23 2011-04-07 Wista Lab Ltd Ligandos para moleculas tau agregadas.
JP2011168515A (ja) 2010-02-17 2011-09-01 Kowa Co エリスロポエチン産生促進作用を有する2−アリールベンゾオキサゾール化合物
US9512092B2 (en) * 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
EP3187495A1 (en) * 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
EP3431472B1 (en) * 2016-03-17 2023-05-03 Checkmate Therapeutics Inc. Novel compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same
JP2018087173A (ja) 2016-11-29 2018-06-07 国立大学法人北海道大学 悪性脳腫瘍治療薬
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
US10676467B2 (en) 2017-06-30 2020-06-09 Washington University Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof

Also Published As

Publication number Publication date
MX2021004134A (es) 2021-07-16
AU2019358074A1 (en) 2021-05-06
JP2022504650A (ja) 2022-01-13
US12473266B2 (en) 2025-11-18
CA3115297A1 (en) 2020-04-16
JP7503850B2 (ja) 2024-06-21
KR20210082466A (ko) 2021-07-05
CN113195084A (zh) 2021-07-30
EP3863755A4 (en) 2022-08-03
BR112021006843A2 (pt) 2021-07-13
US20210387953A1 (en) 2021-12-16
CN113195084B (zh) 2024-04-09
EP3863755A1 (en) 2021-08-18
WO2020077024A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
IL285178A (en) Compounds and uses thereof
IL282998A (en) Pyridazinone compounds and uses thereof
LT3810602T (lt) Junginiai
HUE058687T2 (hu) Azonnali elõkészítés
IL278122B1 (en) Pteridinone compounds and uses thereof
PL3876816T3 (pl) Narzędzie endoskopowe
PT3737403T (pt) Adenovírus modificados
EP3761960C0 (en) OPHTHALMIC FORMULATION
IL282330A (en) Therapeutic compounds
IL280902A (en) Compounds useful as chaperone-mediated autophagy modulators
DK3769019T3 (da) Drivaggregat
IL284514A (en) Halo-allylamine compounds and use thereof
EP3849664C0 (en) PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
IL285118A (en) Compounds and uses thereof
EP3809933A4 (en) CLEANSER
EP3674565A4 (en) HYDRAULIC DRIVE UNIT
EP3864058A4 (en) PHOTOCURABLE COMPOSITION
EP3923876A4 (en) DENTAL DEVICE
LT3867247T (lt) Naujieji junginiai
IL282676A (en) Novel dipeptide compounds and uses thereof
IL282753A (en) Immunogenic composition
EP3806844A4 (en) DOTA COMPOUNDS AND RELATED USES
UA38744S (uk) Монітор
IL285119A (en) Use of spiropidion
IL281762A (en) Arginase1 polypeptides